查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981445

DNA与基因晶片市场：2026-2032年全球市场预测（按产品类型、晶片类型、应用和最终用户划分）

DNA & Gene Chip Market by Product, Chip Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，DNA 和基因晶片市值将达到 108.4 亿美元，到 2026 年将成长到 120.9 亿美元，到 2032 年将达到 236.4 亿美元，复合年增长率为 11.78%。

主要市场统计数据
基准年 2025 108.4亿美元
预计年份：2026年 120.9亿美元
预测年份 2032 236.4亿美元
复合年增长率 (%) 11.78%

简要概述了影响 DNA 和基因晶片生态系统的技术基础、相关人员需求和策略重点，以辅助策略决策。

本执行摘要首先对DNA和基因晶片领域进行了简要概述。它说明了定义当前市场趋势、相关人员需求和实际应用案例的技术基础。探针设计、小型化和数据分析的进步塑造了该领域的未来发展前景，而这些技术演进又与临床需求、学术研究和工业应用紧密相连。基于此背景，读者可以期待一份兼顾科学细微和商业性意义的分析报告。

技术融合、先进分析和不断发展的经营模式正在重塑整个 DNA 和基因晶片价值链的功能和消费者期望。

在工程、资讯科学和临床应用等多方面力量的融合推动下，DNA和基因晶片技术正经历着变革性的转变。小型化和探针密度的提高不断扩大分析通量，使得以往需要多个平台才能完成的实验能够整合到单一晶片的工作流程中。同时，表面化学和杂合反应反应动力学的改进提高了灵敏度和重复性，从而增强了效用。

贸易政策和关税因素的变化正在推动整个行业的供应链重新设计、采购多元化以及对法规的更大程度遵守。

近期贸易政策的发展和关税考量正对DNA和基因晶片市场产生实际影响，迫使企业调整筹资策略、供应商关係和产业计画。许多零件和耗材的供应链仍然高度集中于特定地区，关键材料和製造能力分散在各个国际枢纽。关税措施可能会增加整体成本，扰乱现有的采购节奏，促使企业寻求供应商多元化并重新评估库存策略。

细分市场的趋势揭示了产品设计、应用需求、最终用户工作流程和晶片化学特性如何相互交织，从而决定采用率和商业性差异化。

细分市场分析揭示了不同产品类型、应用、终端用户和晶片类型之间的价值来源和采用模式的差异。在产品层面，标籤和检测试剂盒作为前端试剂仍然至关重要，它们决定着检测的灵敏度和特异性；而微阵列晶片正逐渐成为高通量分析工作流程的基础，并在数据生成基板方面发挥主导作用。微流体耗材推动了样品处理方式的创新，并支援微型化检测。此外，qPCR 阵列提供了实验室用于验证阵列观察结果的正交检验途径。软体和服务在从原始资料中提取价值方面正变得至关重要，它们透过提供分析、工作流程自动化和法规文檔，加快了获得洞见的速度。

区域创新中心、法律规范和基础设施成熟度在全球市场中形成了独特的采用路径和策略挑战。

区域洞察揭示了全球各地不同的创新中心、法规环境和应用速度。美洲地区拥有先进的学术生态系统、强大的临床市场以及大规模的生物技术和製药活动，正在加速高通量平台和整合服务模式的早期应用。北美地区的诊断检查室和製药研发团队专注于监管合规、临床检验和可重复的工作流程，而私人企业则越来越多地投资于国内生产能力和合作伙伴关係，以降低供应链风险。

高效能製造、检验的工作流程和可互通的分析能力，再加上策略伙伴关係关係和明确的智慧财产权，为供应商创造了竞争优势。

竞争格局的核心在于那些在晶片製造领域拥有卓越技术，并具备强大的试剂、软体和服务商业生态系统的公司。主要企业正投资于整合解决方案，透过将高密度晶片和优化的标记化学与检验的工作流程和分析技术相结合，减轻终端用户的负担。策略合作和交叉授权协议加速了技术的应用，并使用户能够获得样品製备和云端数据分析等互补功能。同时，规模小规模、高度专业化的供应商则透过细分市场差异化展开竞争，提供客製化耗材、客製化探针组或针对特定实验或临床需求量身定制的模组化软体。

为高阶主管提供将互通分析、供应链弹性和协同检验整合到可扩展经营模式的实用策略步骤。

产业领导者应采取一系列切实可行的措施，使创新、营运和商业化与不断变化的市场动态保持一致。首先，应优先考虑平台互通性，并投资于能够将原始阵列和晶片数据转化为临床和商业性适用洞察的软体功能。无缝的数据工作流程将降低医院和生物製药客户的采用门槛，并透过软体订阅和分析服务创造持续合作的机会。

透过结合相关人员访谈、技术文献和供应链图谱的严谨研究途径，得出检验且可操作的产业见解。

本研究途径采用定性和定量相结合的方法，以确保获得平衡且基于证据的见解。主要参与者包括学术和研究机构的技术负责人、医院和诊断中心的实验室主任、製药和生物技术公司的高级研发和采购负责人，以及合约研究组织（CRO）的高阶主管，并对他们进行了深入访谈。透过这些访谈，我们探讨了产品性能特征、采购因素、检验要求和伙伴关係选择标准。

技术进步、业务永续营运和以客户为中心的商业化相结合，将决定企业的长期行业领导地位。

总之，DNA和基因晶片产业正处于一个转折点，技术成熟度、数据驱动的价值创造和经营模式创新将决定其竞争优势。晶片化学和微流体的进步拓展了实验的可能性，而整合软体和分析技术则将复杂的输出结果转化为研究人员、临床医生和产业合作伙伴可执行的决策。从学术和研究机构到医院、合约研究组织（CRO）和製药公司，终端用户的多样性要求制定灵活的产品蓝图和量身定制的检验策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：DNA与基因晶片市场：依产品划分

  • 识别牌和检测工具包
  • 微阵列晶片
  • 微流体耗材
  • qPCR晶片
  • 软体和服务

第九章：以晶片类型分類的DNA和基因晶片市场

  • cDNA 晶片
  • 寡核苷酸阵列

第十章：DNA与基因晶片市场：依应用划分

  • 诊断
    • 癌症诊断
    • 遗传疾病的诊断
    • 感染疾病诊断
  • 基因表现分析
  • 基因型鉴定
  • 重测序

第十一章：DNA与基因晶片市场：依最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 医院和诊断检查室
  • 製药和生物技术公司

第十二章 DNA与基因晶片市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：DNA与基因晶片市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 DNA与基因晶片市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国DNA与基因晶片市场

第十六章：中国DNA与基因晶片市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Greiner Bio-One International GmbH
  • Illumina, Inc.
  • Integrated Dna Technologies
  • LifeGen Technologies, LLC
  • Macrogen Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-521BAA36EBAB

The DNA & Gene Chip Market was valued at USD 10.84 billion in 2025 and is projected to grow to USD 12.09 billion in 2026, with a CAGR of 11.78%, reaching USD 23.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.84 billion
Estimated Year [2026] USD 12.09 billion
Forecast Year [2032] USD 23.64 billion
CAGR (%) 11.78%

A concise orientation to technological pillars, stakeholder needs, and strategic priorities shaping the DNA and gene chip ecosystem for strategic decision-making

This executive summary opens with a concise orientation to the DNA and gene chip arena, describing the technological pillars, stakeholder imperatives, and practical use cases that define current market activity. The landscape is shaped by advances in probe design, miniaturization, and data analytics, and these technical evolutions intersect with clinical demand, academic inquiry, and industrial application. Against this backdrop, readers should expect a synthesis that balances scientific nuance with commercial implications.

The introduction frames core objectives: to clarify where innovation concentrates, to identify end-user needs across research and clinical environments, and to profile how product categories and chip types enable distinct workflows. It also outlines how regulatory trends, supply chain resilience, and strategic partnerships influence adoption trajectories. With these priorities established, the remainder of the document provides granular sectoral insights, cross-cutting risks, and practical recommendations for stakeholders seeking to align R&D, manufacturing, and go-to-market initiatives with emergent opportunities.

Technological convergence, advanced analytics, and evolving commercial models are reshaping capabilities and buyer expectations across the DNA and gene chip value chain

The landscape for DNA and gene chip technologies is experiencing transformative shifts driven by converging forces in engineering, informatics, and clinical translation. Miniaturization and higher probe density continue to expand analytical throughput, enabling experiments that once required multiple platforms to be consolidated onto single-chip workflows. Concurrently, improvements in surface chemistries and hybridization kinetics have increased sensitivity and reproducibility, which enhances utility in both research and diagnostic contexts.

At the same time, data science and machine learning have moved from experimental adjuncts to essential components of product value propositions. Sophisticated software pipelines now extract actionable insights from complex expression profiles and genotyping arrays, and vendors who integrate robust analytics with hardware offerings create differentiated solutions. These technological advances coincide with a shift in end-user expectations: academic and research institutes demand flexible, reproducible platforms for discovery, contract research organizations prioritize throughput and standardization, hospitals and diagnostic laboratories require clinically validated workflows, and pharmaceutical and biotechnology companies seek platforms that accelerate biomarker discovery and patient stratification.

Finally, business models are evolving. Software and services are increasingly bundled with consumables and instruments to create recurring revenue streams and deeper customer engagement. As a result, firms that invest in interoperable architectures, customer-centric service models, and partnerships across the value chain will have a strategic advantage in capturing long-term adoption and driving sustained innovation.

Trade policy shifts and tariff considerations have catalyzed supply chain redesigns, sourcing diversification, and regulatory diligence across the industry

Recent trade policy dynamics and tariff considerations have tangible implications for the DNA and gene chip landscape, altering sourcing strategies, supplier relationships, and operational planning. Many component and consumable supply chains remain geographically concentrated, with critical materials and manufacturing capacity located across international hubs. Tariff measures can increase landed costs and disrupt established procurement rhythms, prompting organizations to revisit supplier diversification and inventory policies.

In response, manufacturers and buyers have taken a range of mitigating actions. Some producers have accelerated efforts to localize production or qualify secondary suppliers to reduce exposure to trade uncertainty. Others have restructured contracts to allocate cost volatility more transparently between vendors and buyers, while logistics teams have adopted more dynamic inventory strategies to buffer short-term shocks. These adaptations often introduce additional lead time and require upfront capital, but they reduce the operational risk associated with abrupt policy shifts.

Regulatory compliance and customs classification also command greater attention. Companies spend more resources ensuring correct tariff classifications, pursuing exclusions where appropriate, and engaging with trade advisors to navigate evolving rules. At the same time, supply chain resilience has become a visible strategic priority within corporate governance, with scenario planning and supplier audits integrated into executive-level risk assessments. Ultimately, the cumulative impact of trade measures has catalyzed operational redesigns and strategic repositioning that extend beyond immediate cost effects to shape long-term sourcing, manufacturing, and partnership decisions.

Segment-specific dynamics reveal how product design, application demands, end-user workflows, and chip chemistry converge to determine adoption and commercial differentiation

Segmentation analysis reveals differentiated value drivers and adoption patterns across product categories, applications, end users, and chip types. Product-level dynamics show that labeling and detection kits remain indispensable as front-end reagents that determine assay sensitivity and specificity, while microarray chips anchor high-throughput profiling workflows and serve as the primary data-generating substrate. Microfluidics consumables enable sample handling innovations and support miniaturized assays, and qPCR arrays provide orthogonal validation pathways that laboratories use to confirm array-derived observations. Software and services have become central to deriving value from raw outputs, offering analytics, workflow automation, and regulatory documentation that accelerate time-to-insight.

Application-focused segmentation highlights diagnostic deployments alongside foundational research uses. Diagnostics includes cancer diagnostics, genetic disorder diagnostics, and infectious disease diagnostics, and each subtype imposes distinct requirements for analytical performance, validation, and turnaround. Gene expression profiling remains a core research application that informs mechanistic studies and biomarker discovery, whereas genotyping and resequencing activities cater to variant detection, population studies, and targeted interrogations. End-user segmentation differentiates needs across academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies, with each segment prioritizing factors such as throughput, regulatory readiness, and integration with downstream R&D or clinical workflows.

Chip-type distinctions between cDNA arrays and oligonucleotide arrays further affect platform selection. cDNA arrays typically suit broader transcriptomic surveys and legacy workflows, while oligonucleotide arrays provide higher specificity and compatibility with modern probe design strategies. Consequently, product roadmaps that align chip chemistry with target applications and end-user operational constraints will capture greater adoption and enable more coherent commercial positioning.

Regional innovation hubs, regulatory frameworks, and infrastructure maturity create distinct adoption pathways and strategic imperatives across global markets

Regional insights expose differentiated innovation hubs, regulatory environments, and adoption rhythms across the globe. The Americas combine advanced academic ecosystems, robust clinical markets, and sizable biotechnology and pharmaceutical activity, which together foster early adoption of high-throughput platforms and integrated service models. North American diagnostic laboratories and pharma research teams emphasize regulatory alignment, clinical validation, and reproducible workflows, while commercial players increasingly invest in domestic manufacturing capacity and collaborative partnerships to reduce supply chain risk.

Europe, Middle East & Africa exhibits heterogeneity driven by strong translational research networks, consolidated clinical laboratory networks, and region-specific regulatory frameworks that emphasize patient safety and data integrity. In several European markets, centralized procurement and collaborative research consortia accelerate standardized platform adoption, whereas in some EMEA geographies, fragmented healthcare systems and variable infrastructure shape a more gradual uptake.

Asia-Pacific stands out for its large-scale manufacturing capabilities, expanding clinical diagnostics markets, and growing research funding. Regional manufacturing hubs support global supply chains for chips and consumables, and rising investments in genomic medicine push demand for both high-throughput discovery tools and clinical assays. Across these regions, differences in reimbursement policy, regulatory timelines, and infrastructure maturity inform go-to-market strategies and partnership models, making regionally tailored commercialization plans essential.

Competitive advantage accrues to providers that integrate high-performance manufacturing, validated workflows, and interoperable analytics with strategic partnerships and IP clarity

Competitive dynamics center on firms that blend technical excellence in chip fabrication with robust commercial ecosystems for reagents, software, and services. Leading companies invest in integrated offerings that reduce friction for end users, pairing high-density chips and optimized labeling chemistry with validated workflows and analytics. Strategic alliances and cross-licensing agreements accelerate technology diffusion and enable access to complementary capabilities such as sample preparation or cloud-based data interpretation. At the same time, smaller and more specialized vendors compete on niche differentiation-offering tailored consumables, bespoke probe sets, or modular software that address specific experimental or clinical needs.

Intellectual property and platform interoperability remain pivotal. Firms that secure broad patent coverage for probe designs, surface chemistries, and data processing methods can sustain premium positioning, while vendors that prioritize open standards and seamless integration drive broader ecosystem adoption. Manufacturing scale and quality systems influence pricing and reliability, particularly for customers in regulated environments. Finally, companies that demonstrate transparent validation pathways, responsive technical support, and clear regulatory strategies build stronger trust with hospitals, diagnostic labs, and pharmaceutical partners.

Practical strategic steps for executives to integrate interoperable analytics, supply chain resilience, and collaborative validation into scalable commercial models

Industry leaders should pursue a set of pragmatic actions to align innovation, operations, and commercialization with evolving market dynamics. First, prioritize platform interoperability and invest in software capabilities that turn raw array or chip data into clinically and commercially actionable insights. Seamless data workflows reduce adoption friction for hospitals and biopharma clients and create recurring engagement opportunities through software subscriptions and analytics services.

Second, strengthen supply chain resilience by qualifying multiple suppliers for critical components, assessing nearshoring options where feasible, and enhancing inventory visibility. These measures reduce vulnerability to trade policy shifts and logistical disruptions while maintaining service levels for diagnostic laboratories and research partners. Third, accelerate collaborative validation initiatives with end users across academic institutions, contract research organizations, and clinical labs to generate real-world evidence and streamline regulatory submission pathways. Such partnerships also refine product-market fit and shorten commercialization timelines.

Finally, adopt flexible commercial models that bundle consumables, instruments, and analytics into outcome-oriented offerings. Structured training, technical support, and application-specific pre-validated kits lower adoption barriers and improve customer retention. By executing on these priorities, organizations will convert technical superiority into sustainable market presence and long-term partnerships.

A rigorous research approach combining stakeholder interviews, technical literature, and supply chain mapping to generate validated and actionable industry insights

The research approach combined qualitative and quantitative techniques to ensure balanced, evidence-based insights. Primary engagement included in-depth interviews with technical leaders across academic and research institutes, laboratory directors from hospitals and diagnostic centers, senior R&D and procurement professionals at pharmaceutical and biotechnology companies, and executives at contract research organizations. These conversations explored product performance attributes, procurement drivers, validation requirements, and partnership preferences.

Secondary research encompassed technical literature, regulatory guidance documents, patent filings, and publicly available company disclosures to corroborate technological claims and trace historical development pathways. Supply chain mapping leveraged trade databases and manufacturing registries to identify concentration points for key components and assembly operations. Cross-validation steps synthesized primary feedback with secondary evidence to identify consistent patterns, stress test assumptions, and highlight divergent perspectives across regions and end users.

Analytical rigor was maintained through methodical source triangulation, documented interview protocols, and a transparent approach to classification of product, application, end-user, and chip-type segments. Where appropriate, sensitivity analyses helped contextualize operational risk factors such as tariff exposure and supplier concentration, enabling pragmatic recommendations grounded in observed market behavior.

Synthesis of technological progress, operational resilience, and customer-oriented commercialization that collectively determine long-term sector leadership

In conclusion, the DNA and gene chip sector stands at an inflection point where technical maturation, data-driven value creation, and commercial model innovation collectively define competitive advantage. Advances in chip chemistry and microfluidics expand experimental possibilities, while integrated software and analytics convert complex outputs into practical decisions for researchers, clinicians, and industry partners. End-user diversity-from academic and research institutes to hospitals, contract research organizations, and pharmaceutical companies-necessitates adaptable product roadmaps and tailored validation strategies.

Additionally, external pressures such as trade policies and evolving regulatory expectations have prompted organizations to revisit supply chain and sourcing strategies, reinforcing the importance of resilience and proactive risk management. Firms that align manufacturing capabilities, intellectual property, and interoperable analytics with customer-centric service models will be best positioned to capitalize on both near-term adoption and long-term growth opportunities. The overarching imperative is clear: integrate technical excellence with strategic operational design to transform scientific capability into reproducible, scalable value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA & Gene Chip Market, by Product

  • 8.1. Labeling And Detection Kits
  • 8.2. Microarray Chips
  • 8.3. Microfluidics Consumables
  • 8.4. qPCR Arrays
  • 8.5. Software And Services

9. DNA & Gene Chip Market, by Chip Type

  • 9.1. cDNA Arrays
  • 9.2. Oligonucleotide Arrays

10. DNA & Gene Chip Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cancer Diagnostics
    • 10.1.2. Genetic Disorder Diagnostics
    • 10.1.3. Infectious Disease Diagnostics
  • 10.2. Gene Expression Profiling
  • 10.3. Genotyping
  • 10.4. Resequencing

11. DNA & Gene Chip Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals And Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotechnology Companies

12. DNA & Gene Chip Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA & Gene Chip Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA & Gene Chip Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA & Gene Chip Market

16. China DNA & Gene Chip Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Danaher Corporation
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Greiner Bio-One International GmbH
  • 17.11. Illumina, Inc.
  • 17.12. Integrated Dna Technologies
  • 17.13. LifeGen Technologies, LLC
  • 17.14. Macrogen Inc.
  • 17.15. PerkinElmer, Inc.
  • 17.16. QIAGEN N.V.
  • 17.17. Takara Bio Inc.
  • 17.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA & GENE CHIP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA & GENE CHIP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA & GENE CHIP MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA & GENE CHIP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA & GENE CHIP MARKET SIZE, BY LABELING AND DETECTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA & GENE CHIP MARKET SIZE, BY MICROFLUIDICS CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA & GENE CHIP MARKET SIZE, BY QPCR ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA & GENE CHIP MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CDNA ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA & GENE CHIP MARKET SIZE, BY OLIGONUCLEOTIDE ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENETIC DISORDER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA & GENE CHIP MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA & GENE CHIP MARKET SIZE, BY RESEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA & GENE CHIP MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA & GENE CHIP MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA & GENE CHIP MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA & GENE CHIP MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA & GENE CHIP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DNA & GENE CHIP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DNA & GENE CHIP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GCC DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. G7 DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. NATO DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. NATO DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA & GENE CHIP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA DNA & GENE CHIP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA DNA & GENE CHIP MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA DNA & GENE CHIP MARKET SIZE, BY CHIP TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA DNA & GENE CHIP MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DNA & GENE CHIP MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DNA & GENE CHIP MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)